News and views for the UB community
research news
Researchers discover how a gene only some of us have may protect against neurodegeneration
Fluorescent confocal images of neuronal cells differentiated from the iPSC model were stained with actin (green) and VASP (red). In CHRFAM7A carrier cells (right), actin and VASP co-localize at the membrane surface, strengthening the neuronal structure and facilitating shape change, adhesion, motility and cell-cell interaction. Image on the left shows the neuron without the active gene. Image created by Kinga Szigeti and colleagues.
By ELLEN GOLDBAUM
Published September 22, 2023
UB researchers have discovered how an active form of a gene present in 75% of the human population works to protect the brain against neurodegeneration.
Published online in July in eBiomedicine and highlighted online this week, the findings provide insight into how the active form of CHRFAM7A helps strengthen brain structure in a way that is neuroprotective against diseases such as Alzheimer’s disease.
The study found that the active form of the CHRFAM7A gene activates the actin cytoskeleton, which provides structural support to cells, thus helping to make brain cells more resistant to stiffness, essentially becoming more flexible.
“Actin acts like beams in a house. It provides support for the cells in the cytoskeleton, which is the frame of the cell,” says Kinga Szigeti, corresponding author, professor of neurology in the Jacobs School of Medicine and Biomedical Sciences and a physician with UBMD Neurology. “For the 75% of people who have the active version of CHRFAM7A, it may allow neurons to build stronger connections and to better adapt to changes in the brain environment.”
The gene, CHRFAM7A, is a fusion of a gene that codes for the Alpha 7 receptor for acetylcholine, a neurotransmitter involved in memory and learning, and long associated with Alzheimer’s and a kinase, a type of enzyme.
Three-quarters of the population has the active version while a quarter of the population does not. And it’s only present in humans, not animals, which, Szigeti explains, is why animal models of Alzheimer’s disease and other neurodegenerative diseases often don’t accurately predict how drugs will function in humans.
CHRFAM7A has also been implicated in many neuropsychiatric disorders, such as schizophrenia and bipolar disease.
“In this paper we show that this gene makes human brain cells develop stronger connections,” Szigeti explains.
“It’s a very interesting conundrum,” says Szigeti, who is also director of UB’s Alzheimer’s Disease and Memory Disorders Center. “If you don’t have CHRFAM7A or you have less of it, you are at higher risk of developing Alzheimer’s disease because the brain is less structurally solid. But if you do have the active form of the gene, the drugs that we have now may not work as well because the Alpha 7 receptor for acetylcholine — which is what most drugs target — is altered.”
Szigeti says the whole reason behind conducting this study was that there’s a translational gap in a lot of the very important genes affecting humans, especially those implicated in Alzheimer’s disease and psychiatric disorders.
“Neuroscience research has been overwhelmingly based on animal models,” she says, “but these diseases affect higher cognitive functions that are specific to humans and not present in mice, for example. This work is helping to fill in that translational gap.”
To do the study, the researchers developed human-induced pluripotent stem cells taken from the skin of adults who had Alzheimer’s disease and transformed them into neurons, creating essentially brain cells in a dish.
Partial funding was provided by the Community Foundation for Greater Buffalo and the Alzheimer’s Association.
UB co-authors are Ivanna Ihnatovych, Nicolas Rosas, Ryu P. Dorn, Emily Notari, Muye He, Ivan Maly, Shreyas Prasad, Erik Nimmer, Yuna Heo, Wilma A. Hofmann, Arnd Pralle and Yongho Bae. Other co-authors are from Roswell Park Comprehensive Cancer Center, National University of San Martin (Argentina), and Rush University Medical Center.